
Development and provision of medicines for rare diseases in endocrinology, oncology-hematology, and metabolic therapy areas.
B
CSR Analysis score
The organization is among the top 20% of most committed organizations, excluding the top 5%, among comparable organizations.
EmpCo Directive — September 27, 2026
We analyzed the websites of over 250,000 companies, including Orphan Europe's, to extract CSR initiatives and communications containing risky environmental claims.
Greenwashing risk score + your position within your sector
+250,000
Total organizations analyzedAnalysis by axis
Access the detailed report with all sector benchmarks, in-depth competitive analysis and actionable recommendations.
Methodology: Score calculated according to 6 CSR themes (Carbon, Biodiversity, Circular Economy, Sustainable Investments, Governance, Social Impact)
Sources: Public data, CSR reports, documented initiatives, official databases
Last update: August 2026
This analysis is not yet available in English. Please see the French version.
Leading organizations
Fresenius Kabi
B
Development and provision of life-saving drugs and medical technologies for patients with serious and chronic diseases, including pharmaceuticals, clinical nutrition, and medical devices.
Sebia
B
Development and provision of in vitro diagnostic equipment and reagents for screening and monitoring various diseases, primarily in oncology, diabetes, hemoglobinopathies, autoimmune, and infectious diseases.
Novo Nordisk
A
Development and production of pharmaceuticals for diabetes, obesity, growth disorders, and rare bleeding conditions, including insulins and GLP-1 analogues.
Initiatives identified among leaders
Réduction énergétique et consommation d'eau sur le site de Chartres
“Le site de production de Chartres améliore ses pro...” - Novo NordiskRéduction globale de l'impact environnemental par des actions structurées
“Le groupe s'engage à réduire son impact environnem...” - Fresenius KabiProgramme de récupération et recyclage des stylos injecteurs jetables.
“Novo Nordisk a lancé en France le programme Returp...” - Novo Nordisk64% of similar organizations communicate on CSR issues
+758 initiatives collected from 50 similar organizations
Is your score incomplete? Update your CSR information and improve your positioning.
Claim this page
Updated data
Personalized recommendations
Access complete data, competitive analyses and actionable recommendations for your clients.
Comprehensive sector benchmarks
Competitive data
Ready-to-use reports